The Incidence of Lymphoma in Beijing:Comparing Results from MIS-CASS(2019)and Beijing Cancer Registry(2017)

Introduction:This study aimed to evaluate the performance of the Medical-Insurance-System-based Cancer Surveillance System(MIS-CASS)in estimating cancer incidence by comparing the results with the Beijing Cancer Registry(BCR),which is one of the highest-quality population-based cancer registries in China.Methods:Using lymphoma as an example,we extracted relevant claims data from the administrative systems of medical insurance in Beijing(2012–2020)and estimated the most current lymphoma incidence in Beijing(2019)using a standard data processing procedure.The absolute number of new cases,crude incidence rate,and age-standardized incidence rate of lymphoma were compared with the latest data reported by the BCR(2017).Results:Both lymphoma incidence rates and age distribution of new cases estimated based on MISCASS were similar to the BCR data(crude incidence rate:9.8/100,000 vs.10.6/100,000).However,because MIS-CASS included more designated hospitals and covered a larger local stationary population irrespective of household registration(hukou),the absolute number of incident lymphoma cases identified by MIS-CASS was 39.1%higher than that reported by the BCR(2,002 vs.1,439).Conclusions:The MIS-CASS approach reflected the actual cancer burden in a more complete and timely manner as compared with the current BCR,providing new insights for improving cancer surveillance strategies in China.